Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in Interstitial Cystitis
NCT02787083Phase 3Terminated
- Sponsor
- Philadelphia Urosurgical Associates
- Start
- Aug 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mirabegron in interstitial cystitis (IC), sponsored by Philadelphia Urosurgical Associates. Started Aug 2016; status: terminated.
02
Drugs
mirabegron
03
Conditions
interstitial cystitis (IC)
Beyond the preview
Go deeper on NCT02787083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787083.